MRK peer analysis
Merck (MRK) against its competitors: price, today's move, 1-year return and market value side by side.
MRK and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ABBV AbbVie | $288.58 | -2.14% | 26.02% | $521.11B |
| AMGN Amgen | $466.86 | 0.18% | 59.76% | $251.94B |
| AZN AstraZeneca | $186.94 | 0.16% | 13.37% | $289.48B |
| GILD Gilead | $170.72 | 0.02% | 43.61% | $211.70B |
| JNJ Johnson & Johnson | $269.64 | -1.30% | 42.50% | $657.68B |
| LLY Eli Lilly | $1,406.84 | -0.75% | 66.41% | $1.26T |
| NVS Novartis | $161.47 | 0.42% | 31.52% | $303.67B |
| PFE Pfizer | $30.91 | 1.28% | 26.86% | $173.95B |
| SNY Sanofi | $45.38 | 2.36% | -10.98% | $106.24B |
| MRK Merck | $148.81 | -0.47% | 72.45% | $368.89B |
- MRK's peers: ABBV (AbbVie), AMGN (Amgen), AZN (AstraZeneca), GILD (Gilead), JNJ (Johnson & Johnson), LLY (Eli Lilly), NVS (Novartis), PFE (Pfizer).
Updated 2026-11-02 19:12 UTC